Key clinical point: The antimalarial agent bruceantin inhibited full length aberrant androgen receptor (AR-FL) and AR variant 7 (AR-V7) in cell cultures of castration-resistant prostate cancer.

Major finding: Bruceantin demonstrated binding to the protein and molecular chaperone HSP90, which prevented the interaction of HSP90 and AR-FL/AR-V7 that contributes to treatment resistance in prostate cancer.

Study details: The data come from an assay test of antimalarial agents including bruceantin (BCT) as potential treatments for castration-resistant prostate cancer.

Disclosures: The study was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare; and the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT). The researchers had no financial conflicts to disclose.